For example, CTLA-4 expression increased in tumors after nivolumab, supporting the rationale for combining anti-CTLA-4 agents with anti-PD-1 agents in the neoadjuvant setting—the first dual ICI combination approved for the frontline treatment of metastatic ccRCC. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.